Custom Search


Tuesday 01 November 2005

Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.

By: Bauwens D, Maerevoet M, Michaux L, Theate I, Hagemeijer A, Stul M, Danse E, Costantini S, Vannuffel P, Straetmans N, Vekemans MC, Deneys V, Ferrant A, Van Den Neste E.

Br J Haematol 2005 Nov;131(3):338-40

We evaluated the combination of rituximab with chlorambucil in patients with mantle cell lymphoma (MCL) not eligible for aggressive therapy. Fourteen patients (male/female: 9/5) were included (two newly diagnosed, 12 relapsed/refractory). The toxicities were neutropenia, thrombopenia and infection. Nine (64%) patients responded; five (36%) achieved complete remission and four (29%) achieved partial remission. The median progression-free survival for responders was 26 months (95% CI, 4-48). Marrow polymerase chain reaction negativity was attained in seven responders. These results suggest that this schedule may have notable antitumour activity in patients with MCL, including patients in relapse after autologous stem cell transplantation.

Use of this site is subject to the following terms of use